InvestorsHub Logo
Followers 51
Posts 1681
Boards Moderated 0
Alias Born 02/15/2007

Re: md1225 post# 107504

Saturday, 01/12/2013 12:52:29 PM

Saturday, January 12, 2013 12:52:29 PM

Post# of 345976
MD1225, not to jump on your case, but why is there this big deal about Avastin being the competition for Bavi?
We all know about the black box warnings that come with Avastin and the relative lack of side effects with bavituximab.
Look at the appoved indications for Avastin

Metastatic Renal Cell Carcinoma
Second-Line Treatment of Glioblastoma
First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC)
Second-Line Treatment of Metastatic Colorectal Cancer
First-Line Treatment of Metastatic Colorectal Cancer

The only overlap with Bavi is first-line NSCLC. Avastin didn't do that well there, but good enough to get approved.

I think Bavi could fit right in with Avastin. Roche can just not do trials with Bavi for the other approved indications.
Bavi could be tested by Roche for breast cancer, pancreatic, liver, etc, anything else..
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News